Anonymous ID: bba89f Dec. 21, 2020, 10:22 a.m. No.12118819   ๐Ÿ—„๏ธ.is ๐Ÿ”—kun

Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites

 

Ability of the patient to be vaccinated in a setting where advanced medical care is immediately available for anaphylaxis

(So if you do die, they can resuscitate you)

 

Antihistamines (e.g., H1 or H2 antihistamines) and bronchodilators do not treat airway obstruction or hypotension, and thus are not first-line treatments for anaphylaxis. However, they can help provide relief for hives and itching (antihistamines) or symptoms of respiratory distress (bronchodilators) but should only be administered after epinephrine in a patient with anaphylaxis. Because anaphylaxis may recur after patients begin to recover, monitoring in a medical facility for several hours is advised, even after complete resolution of symptoms and signs.

 

If anaphylaxis is suspected, take the following steps:

 

Rapidly assess airway, breathing, circulation, and mentation (mental activity).

Call for emergency medical services.

Place the patient in a supine position (face up), with feet elevated, unless upper airway obstruction is present or the patient is vomiting.

Epinephrine (1 mg/ml aqueous solution [1:1000 dilution]) is the first-line treatment for anaphylaxis and should be administered immediately.

In adults, administer a 0.3 mg intramuscular dose using a premeasured or prefilled syringe, or an autoinjector in the mid-outer thigh.

The maximum adult dose is 0.5 mg per dose.

Epinephrine dose may be repeated every 5-15 minutes (or earlier) as needed to control symptoms while waiting for emergency medical services.

Because of the acute, life-threatening nature of anaphylaxis, there are no contraindications to epinephrine administration.

 

December 16, 2020

 

https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/anaphylaxis-management.html